ROLE OF CYTOCHROME P450 3A4 IN THE METABOLISM OF DRUGS USED TO TREAT CHRONIC HEART FAILURE
Issue:
9
Year:
2016
The investigation has shown that a change in CYP3A4 activity may have clinical consequences if a CYP3A4-metabolized drug is used at average therapeutic doses.
Keywords:
renin-angiotensin-aldosterone system
cytochrome P450 3A4
aldosterone
metabolism
chronic heart failure
References:
- Marrel R., Grenner D., Mejs P. i dr. Biohimija cheloveka. T. 2, Per. s angl. / M.: Mir, 2004.
- Kukes V.G. Funktsional'noe sostojanie nekotoryh nejroendokrinnyh sistem u bol'nyh s hronicheskoj nedostatochnost'ju krovoobraschenija (mate-rialy klinicheskih, funktsional'nyh, biohimicheskih, radioizotopnyh i morfologicheskih metodov issledovanija). Dis. … d-ra med. nauk. M., 1970.
- Kashaeva O.V. Sostojanie metabolicheskoj funktsii pecheni i optimiza tsija farmakoterapii u bol'nyh hronicheskoj serdechnoj nedostatochnost'ju. Avtoref. dis. ... kand. med. nauk. M., 2002; 19 s.
- Ramenskaja G.V. Hromatograficheskoe opredelenie lekarstvennyh sredstv i ih metabolitov dlja fenotipirovanija izofermentov tsitohroma P450 // Himiko-farmatsevticheskij zhurnal: nauchno-tehnicheskij i proizvod-stvennyj zhurnal. – 2005; 39 (2): 53–6.
- Sherlock S., Dick R., Van Leeuwen D. Liver biopsy today. The Royal Free Hospital experience // J. Hepatol. – 1985; 1 (1): 75–85.
- Johnston D., Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure // Am. J. Cardiol. – 1992; 70 (10): 109–12.
- Berkowitz D. The differential diagnosis of the coronary artery disease and gastrointestinal disorders // Am. J. Cardiol. – 1963; 12: 354–7.
- Higgins C., Vatner S., Braunwald E. Postprandial redistribution of regional blood flow at rest and during exercise in conscious dogs with experimental hear
- Shumjantseva V.V., Mahova A.A., Bulko T.V. i dr. Vlijanie antioksidan tov na elektrokataliticheskuju aktivnost' tsitohroma R450 3A4 // Biomed. Himija. – 2014; 60 (2): 224–34.
- Archakov A., Bachmanova G. Cytochrome P450 and Active Oxygen / 1 London: Taylor and Francis, 1990.
- Mahova A.A., Shumjantseva V.V., Shih E.V. i dr. Reguljatsija aktivnosti 20. fermentov metabolizma lekarstvennyh preparatov – tsitohromov R450 3A4 i 2S9 – biologicheski aktivnymi soedinenijami // Molekuljarnaja meditsina. – 2013; 5: 49–53.
- Otdelenov V.A., Smirnov V.V., Dmitriev A.V. i dr. Vlijanie etilmetil gidroksipiridinamalata na aktivnost' CYP3A4: kompleksnyj podhod k otsenke vlijanija na sistemu biotransformatsii lekarstvennyh sredstv // Lekarstvennye preparaty i ratsional'naja farmakoterapija. – 2013; 3: 30–6.
- Kattsung-Bertram G. Bazisnaja i klinicheskaja farmakologija. T. 1 / SPb: 22. Nevskij Dialekt, 1998; s. 73–86
- Manujlov V.G., Luchkevich V.S., Rumjantsev A.P. i dr. Osnovy nauchnolite raturnoj raboty v meditsine / SPb: SPbGMA im. I.I. Mechnikova, 1996; 125.
- Felix C., Walker A., Lange B. et al. Association of CYP3A4 genotype with 24. treatment-related leukemia // Proc. Natl. Acad. Sci. USA. – 1998; 95 (22): 13176–81.
- Kukes V., Sychev D., Ramenskaja V. i dr. Otsenka aktivnosti izofermenta tsitohroma R450 3A4 (CYP3A4) kak real'naja vozmozhnost' personalizatsii farmakoterapii // Vrach. – 2008; 3: 13–9. t failure // Am. J. Cardiol. – 1974; 34 (3): 318–24.
- Zelis R., Nellis S., Longhurst J. et al. Abnormalities in the regional . circulations accompanying congestive heart failure // Prog. Cardiovasc. Dis. – 1975; 18 (3): 181–99.
- Partharasarathy H., Menard J., White W. et al. A double-blind randomized . study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism // J. Hypertens. – 2011; 29: 980–90.
- Sychev D.A., Ramenskaja G.V., Ignat'ev I.V. i dr. Klinicheskaja farma kogenetika. Pod red. V.G. Kukesa, N.P. Bochkova / M.: GEOTAR-Media, 2007; 248 s.
- Luk'janova L.D. Sovremennye problemy i perspektivy farmakologi-12. cheskoj korrektsii gipoksicheskih sostojanij. V kn.: Farmakoterapija v nevro-logii i psihiatrii / M., 2002; s. 22–34.
- Smirnov A.V., Krivoruchko B.I. Antigipoksanty v neotlozhnoj meditsi-13. ne // Anesteziologija i reanimatologija. – 1998; 2: 50–5.
- Luk'janchuk V.D., Savchenkova L.V. Antigipoksanty: sostojanie i perspek-14. tivy // Eksperim. i klin. farmakol. – 1998; 61 (4): 72–9.
- Negovskij V.A., Zolotokrylina E.S. Postreanimatsionnaja bolezn' / M.: 15. Meditsina, 1987; 480.
- Luk'janova L.D. Novye podhody k sozdaniju antigipoksantov metabo-16. licheskogo dejstvija // Vestnik RAMN. – 1999; 3: 18–25.
- Stoljarova V.V. Issledovanie kardioprotektornogo dejstvija prepara-17. tov s antioksidantnoj aktivnost'ju pri ostroj ishemii golovnogo mozga // Eksperim. i klin. farmakol. – 2001; 64 (6): 31–3.